IRON | Ticker Profile - Titan Protect

IRON

Disc Medicine, Inc.

Healthcare · Biotechnology · NGM

$67.00

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.7B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-9.30

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-35.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$100.00

+49% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 11 analysts covering this stock

About Disc Medicine, Inc.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.

https://www.discmedicine.com

Country: United States Employees: 154 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.929

Good returns relative to risk taken

Kelly Fraction

0.0802

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.901

Acceptable balance between returns and drawdown risk

Annual Return

44.3%

Historical annualised return based on price data

Max Drawdown

-49.2%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.14

Significantly more volatile than the market

52W High

$99.50

33% below the year high

52W Low

$40.00

68% above the year low

Avg Volume

491,791

Average daily shares traded — higher means easier to buy and sell

Short Ratio

12.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

17.3%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-6.64

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

4.51

Heavy leverage — higher financial risk if revenues decline

Current Ratio

24.00

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

23.45

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-121,395,752

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-241,603,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$128.00

Target Median

$100.00

Target Low

$79.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go